TY - JOUR
T1 - Health-related quality of life for normal glycaemia, prediabetes and type 2 diabetes mellitus
T2 - Cross-sectional analysis of the ADDITION-PRO study
AU - Leal, Jose
AU - Becker, Frauke
AU - Feenstra, Talitha
AU - Pagano, Eva
AU - Jensen, Troels Mygind
AU - Vistisen, Dorte
AU - Witte, Daniel R.
AU - Jorgensen, Marit Eika
N1 - Funding Information:
This work is part of the RHAPSODY study which is supported by Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. D.R.W. is funded by an unrestricted grant from the Danish Diabetes Academy supported by the Novo Nordisk Foundation. The ADDITION‐PRO study was funded by an unrestricted grant from the European Foundation for the Study of Diabetes/Pfizer for Research into Cardiovascular Disease Risk Reduction in Patients with Diabetes (74550801), by the Danish Council for Strategic Research and by internal research and equipment funds from Steno Diabetes Center. The funders of the current study had no role in the collection, analysis, or interpretation of the data. They had no role in study design or writing of the manuscript.
Publisher Copyright:
© 2022 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
PY - 2022/6
Y1 - 2022/6
N2 - Aims: We estimated and compared health-related quality of life for individuals with normal glucose tolerance, prediabetes and diabetes. Methods: Participants in the ADDITION-PRO study, Denmark, who attended a health assessment between 2009 and 2011, and who completed the 3-level EuroQoL 5-dimensions (EQ-5D-3L) questionnaire were included. For the present study, they were classified as normal glucose tolerance, prediabetes and diabetes (screen-detected and known) using the 2019 American Diabetes Association criteria. Prediabetes was defined as impaired fasting glucose, impaired glucose tolerance or HbA1c between 5.7–6.4% (39–47 mmol/mol). EQ-5D-3L data were converted into utility scores using Danish and UK values, where ‘1’ equals full health and ‘0’ equals death. Regression models estimated the association between utility and the different glucose health states. Results: The mean EQ-5D-3L score in the sample population was 0.86 ± 0.17 (median 0.85, interquartile range 0.76 to 1) using UK values. Almost half of the sample (48%) reported full health with an EQ-5D score of ‘1’. Individuals with known diabetes reported the lowest EQ-5D-3L utility scores (0.81 ± 0.20), followed by individuals with screen-detected diabetes (0.85 ± 0.19), prediabetes (0.86 ± 0.17) and normal glucose tolerance (0.90 ± 0.15). The differences were statistically significant for normal glucose and known diabetes relative to prediabetes, after adjusting for sex, age, smoking, BMI and physical activity. These findings also held using Danish values albeit the differences were of smaller magnitude. Conclusions: Having prediabetes and diabetes was significantly associated with lower health-related quality of life relative to normal glucose tolerance. Our estimates will be useful to inform the value of interventions to prevent diabetes or prediabetes.
AB - Aims: We estimated and compared health-related quality of life for individuals with normal glucose tolerance, prediabetes and diabetes. Methods: Participants in the ADDITION-PRO study, Denmark, who attended a health assessment between 2009 and 2011, and who completed the 3-level EuroQoL 5-dimensions (EQ-5D-3L) questionnaire were included. For the present study, they were classified as normal glucose tolerance, prediabetes and diabetes (screen-detected and known) using the 2019 American Diabetes Association criteria. Prediabetes was defined as impaired fasting glucose, impaired glucose tolerance or HbA1c between 5.7–6.4% (39–47 mmol/mol). EQ-5D-3L data were converted into utility scores using Danish and UK values, where ‘1’ equals full health and ‘0’ equals death. Regression models estimated the association between utility and the different glucose health states. Results: The mean EQ-5D-3L score in the sample population was 0.86 ± 0.17 (median 0.85, interquartile range 0.76 to 1) using UK values. Almost half of the sample (48%) reported full health with an EQ-5D score of ‘1’. Individuals with known diabetes reported the lowest EQ-5D-3L utility scores (0.81 ± 0.20), followed by individuals with screen-detected diabetes (0.85 ± 0.19), prediabetes (0.86 ± 0.17) and normal glucose tolerance (0.90 ± 0.15). The differences were statistically significant for normal glucose and known diabetes relative to prediabetes, after adjusting for sex, age, smoking, BMI and physical activity. These findings also held using Danish values albeit the differences were of smaller magnitude. Conclusions: Having prediabetes and diabetes was significantly associated with lower health-related quality of life relative to normal glucose tolerance. Our estimates will be useful to inform the value of interventions to prevent diabetes or prediabetes.
KW - EQ-5D utility
KW - health-related quality of life; prediabetes
KW - Cross-Sectional Studies
KW - Humans
KW - Quality of Life
KW - Surveys and Questionnaires
KW - Glucose
KW - Health Status
KW - Diabetes Mellitus, Type 2/epidemiology
KW - Prediabetic State/epidemiology
U2 - 10.1111/dme.14825
DO - 10.1111/dme.14825
M3 - Journal article
C2 - 35253278
AN - SCOPUS:85126003072
SN - 0742-3071
VL - 39
JO - Diabetic Medicine
JF - Diabetic Medicine
IS - 6
M1 - e14825
ER -